Caixin
Apr 16, 2022 05:26 PM
CHINA

Two Sinopharm Shots That Target Omicron to Start Hong Kong Trials

A healthcare worker prepares a dose of Sinovac Biotech Ltd. Covid-19 vaccine at a community vaccination center in Hong Kong, China, on Sunday, Feb. 27, 2022. The city is battling to contain an outbreak of the omicron variant of the virus that has strained its healthcare system, and raised questions about its Covid Zero strategy. Photographer: Justin Chin/Bloomberg
A healthcare worker prepares a dose of Sinovac Biotech Ltd. Covid-19 vaccine at a community vaccination center in Hong Kong, China, on Sunday, Feb. 27, 2022. The city is battling to contain an outbreak of the omicron variant of the virus that has strained its healthcare system, and raised questions about its Covid Zero strategy. Photographer: Justin Chin/Bloomberg

(Bloomberg) -- A China National Pharmaceutical Group Co. unit said it’s received approval to start clinical trials in Hong Kong of two inactivated vaccines that target the omicron variant of coronavirus.

China National Biotec Group Company Ltd., a vaccine-developing subsidiary of the state-owned pharmaceutical giant known as Sinopharm, announced the news on its WeChat account on Saturday. The trials will look at the safety of the inoculations and their ability to stimulate an immune response in adults who have received two or three doses.

You've accessed an article available only to subscribers
VIEW OPTIONS
Share this article
Open WeChat and scan the QR code